Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
 

Vincenzo Cerundolo

Default user avatar

Boosting the immune system to treat cancer

University of Oxford
University Offices
Wellington Square
Oxford
OX1 2JD
United Kingdom

Email: vincenzo.cerundolo@molecular-medicine.oxford.ac.uk
Tel: 01865 222412

Based at the University of Oxford, Professor Vincenzo Cerundolo is an expert in immunotherapy – treatments that harness a patient’s own immune system to destroy tumours. Immunotherapy has the potential to be a powerful treatment for cancer, but at the moment it is not as effective as it could be. Professor Cerundolo and his team are working on ways to improve immunotherapy, pushing forward this exciting new treatment to bring benefits to people with cancer.

Cancer vaccines

Professor Cerundolo’s research focuses on improving immunotherapy treatments known as cancer vaccines. These are different from preventive vaccines that people have to stop them picking up infections like measles or TB.

Instead, cancer vaccines are given to people who already have cancer, ‘training’ the immune system to recognise and destroy cancer cells throughout the body. But clinical trials have shown that cancer vaccines don’t boost the immune system as much as they could do.

Professor Cerundolo and his team are carrying out an in-depth investigation of how the immune system responds to cancer vaccines, studying the different types of immune cells involved. Through their research they hope to hit on ways to improve the effectiveness of cancer vaccines, which could save many lives in the future.

Research in Professor Cerundolo's laboratory is focused on the understanding of the mechanisms which control the cell-cell interplay required for optimal expansion and activation of tumour-specific T cell populations.

Other research projects by Vincenzo Cerundolo

Biological Sciences Committee (BSC) Programme Grants
Funding period: 01 October 2009 to 30 September 2014

Publications


Synthesis of truncated analogues of the iNKT cell agonist, alpha-galactosyl ceramide (KRN7000), and their biological evaluation

Bioorg Med Chem.2011;19 :221-228

Quantitating T cell cross-reactivity for unrelated peptide antigens

J Immunol.2009;183 :4337-4345